News | October 21, 2013

FDA Recall: Bard LifeStent Solo Vascular Stent May Fail to Deploy

stents peripheral artery disease pad devices fda lifestent solo vascular bard

October 21, 2013 — Bard Peripheral Vascular has sent an urgent Class I medical device recall notification letter informing customers of the problems of the LifeStent Solo vascular stent and the actions customers should take. The LifeStent Solo vascular stent is an implantable self-expanding stent and delivery system used to improve the superficial femoral artery (SFA) luminal diameter in the treatment of atherosclerotic lesions.

The FDA reported the deployment mechanism for the device may not perform properly when used. Deployment issues range from failure to deploy, partial deployment and difficult deployment. This product may cause serious adverse health consequences, including possible complications of bleeding, loss of limb, heart attack, stroke, vascular surgery and/or death.

Customers were instructed to do the following:

  • Complete the Recall and Effectiveness Check Form (even if they no longer have the recalled product) and fax form to Bard Peripheral Vascular at 1-800-994-6772; and
  • Call Bard Peripheral Vascular’s recall coordinator at 1-800-321-4254 to receive a Return Authorization Number or Consignment Recall Number.


For more information: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=122212


Related Content

News | Peripheral Artery Disease (PAD)

March 20, 2024 — Biotronik has been granted Breakthrough Device Designation (BDD) from the US Food and Drug ...

Home March 20, 2024
Home
News | Peripheral Artery Disease (PAD)

February 12, 2024 — Sensome, a company pioneering the connected medical device revolution with the world’s smallest ...

Home February 12, 2024
Home
News | Peripheral Artery Disease (PAD)

November 10, 2023 —Getinge announced commercial availability of the iCast covered stent system in the United States for ...

Home November 10, 2023
Home
News | Peripheral Artery Disease (PAD)

October 24, 2023 — Four years ago, following a publication based on the limited data available, the U.S. Food and Drug ...

Home October 24, 2023
Home
News | Peripheral Artery Disease (PAD)

September 14, 2023 — LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of ...

Home September 14, 2023
Home
News | Peripheral Artery Disease (PAD)

July 11, 2023 — The U.S. Food and Drug Administration (FDA) is informing healthcare providers about updated information ...

Home July 11, 2023
Home
News | Peripheral Artery Disease (PAD)

June 21, 2023 — A new science report issued by the American Heart Association (AHA) emphasizes the importance of ...

Home June 21, 2023
Home
News | Peripheral Artery Disease (PAD)

June 16, 2023 — Endologix LLC, a privately held, global medical device company, dedicated to providing disruptive ...

Home June 16, 2023
Home
News | Peripheral Artery Disease (PAD)

June 15, 2023 — Endologix LLC, a privately held, global medical device company dedicated to providing disruptive ...

Home June 15, 2023
Home
News | Peripheral Artery Disease (PAD)

March 8, 2023 — Treatments for peripheral artery disease (PAD) were largely developed in men and are less effective in ...

Home March 08, 2023
Home
Subscribe Now